CERITINIB EXCLUSION CRITERIA: Male sterilization (at least 6 months prior to screening); the vasectomized male partner should be the sole partner for that subject; use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception
Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
Use of oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
Use of oral, injected or implanted hormonal methods of contraception or
Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
Oral, injected or implanted hormonal contraception
Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
Established use of oral, injected, or implanted hormonal methods of contraception or use of a barrier method of contraception.
Use of oral, injected or implanted hormonal methods of contraception or;
Women using any form of hormonal contraception (oral, injected, implanted, transdermal) will be excluded (unless they are willing to switch to another effective form of contraception under their physician's guidance) Additional exclusion criteria for PDR001/HDM201-
Established use of oral, injected or implanted hormonal methods of contraception.
Established use of oral, injected or implanted hormonal methods of contraception.
For ARMs A, C and D, oral contraception (OC), injected or implanted hormonal methods are not allowed as BKM120 and potentially decreases the effectiveness of hormonal contraceptives; for ARM B, oral contraceptives, injected or implanted hormonal methods are not allowed as the sole method of contraception, as BYL719 has not been characterized with respect to its potential to interfere with the PK and/or the effectiveness of OCs
Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
Established use of oral, injected, or implanted hormonal method of contraception by the female partner
Established use of oral, injected, or implanted hormonal method of contraception by the female partner performed at least 6 months before screening;
Oral*/ injected/ implanted/ transdermal hormonal contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), e.g., hormone vaginal ring.
Established use of oral, injected or implanted hormonal methods of contraception.
Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
Established use of oral, injected or implanted hormonal methods of contraception
